Novartis to conduct additional trial of Rasilez
Rasilez is the first-in-class oral direct renin inhibitor. The development of Rasile...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
